Early cancer detection startup Craif raises $22M in Series C funding led by X&KSK to expand into the U.S. market and enhance R&D efforts.
Early cancer detection startup Craif raises $22M in Series C funding led by X&KSK to expand into the U.S. market and enhance R&D efforts.
04/28/25, 2:29 AM
Location
bunkyoMoney raised
$22 million
Industry
biotechnology
Round Type
series c
Investors
Aozora Bank Group, Daiwa House Industry, Tauns Laboratories, Unreasonable Group, X&Ksk
Craif has secured $22 million in Series C funding to further develop its AI-powered early cancer detection software using microRNA. The funding, led by existing investor X&KSK, aims to enhance its presence in the U.S. market and bolster research and development efforts. This brings Craif’s total funds raised to $57 million
Company Info
Location
5f hongo itp office , 2-25-7 yushima
bunkyo, tokyo, japan
Additional Info
Craif is a molecular diagnostics company leveraging miRNA and machine learning for early cancer detection. Our proprietary platform, launched in Japan in 2022, powers the miSignal test, which screens for seven cancers (pancreatic, ovarian, esophageal, lung, breast, colorectal, and gastric) and has seen over 400% YoY revenue growth.
In parallel with the commercialization of miSignal, we have started the clinical trial for the IVD test - pancreatic cancer diagnostic test for high risk population (e.g. diabetes, pancreatitis, etc.). This is a test seeking FDA/PMDA approval and planned to be reimbursed by insurance companies in the U.S. and reimbursed by the National Healthcare System in Japan. The clinical trial in Japan started in April 2024 and is planned to obtain approval in 2027H1.